DE69727558D1 - Humanes cyr61, ein signalmolekül der extrazellulaeren matrix - Google Patents

Humanes cyr61, ein signalmolekül der extrazellulaeren matrix

Info

Publication number
DE69727558D1
DE69727558D1 DE69727558T DE69727558T DE69727558D1 DE 69727558 D1 DE69727558 D1 DE 69727558D1 DE 69727558 T DE69727558 T DE 69727558T DE 69727558 T DE69727558 T DE 69727558T DE 69727558 D1 DE69727558 D1 DE 69727558D1
Authority
DE
Germany
Prior art keywords
ecm signalling
signalling molecules
mammalian ecm
cyr61
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727558T
Other languages
English (en)
Other versions
DE69727558T2 (de
Inventor
F Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Munin Corp
Original Assignee
Munin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munin Corp filed Critical Munin Corp
Publication of DE69727558D1 publication Critical patent/DE69727558D1/de
Application granted granted Critical
Publication of DE69727558T2 publication Critical patent/DE69727558T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DE69727558T 1996-03-15 1997-03-14 Humanes CYR61, ein Signalmolekül der extrazellularen Matrix Expired - Lifetime DE69727558T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1395896P 1996-03-15 1996-03-15
US13958P 1996-03-15
PCT/US1997/004193 WO1997033995A2 (en) 1996-03-15 1997-03-14 Extracellular matrix signalling molecules

Publications (2)

Publication Number Publication Date
DE69727558D1 true DE69727558D1 (de) 2004-03-18
DE69727558T2 DE69727558T2 (de) 2004-12-16

Family

ID=21762734

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69727558T Expired - Lifetime DE69727558T2 (de) 1996-03-15 1997-03-14 Humanes CYR61, ein Signalmolekül der extrazellularen Matrix

Country Status (11)

Country Link
US (3) US6413735B1 (de)
EP (1) EP0888452B1 (de)
JP (1) JP4307552B2 (de)
CN (1) CN1263852C (de)
AT (1) ATE259419T1 (de)
AU (1) AU733382B2 (de)
CA (1) CA2248549A1 (de)
DE (1) DE69727558T2 (de)
DK (1) DK0888452T3 (de)
HK (1) HK1018707A1 (de)
WO (1) WO1997033995A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT804562E (pt) 1994-07-12 2003-02-28 Human Genome Sciences Inc Factor 2 de crescimento de tecido conjuntivo
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
US7521540B2 (en) 1996-03-15 2009-04-21 Munin Corporation CYR61 compositions and methods
WO1997033995A2 (en) 1996-03-15 1997-09-18 Munin Corporation Extracellular matrix signalling molecules
WO1999033878A1 (fr) 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN1796556A (zh) * 1998-03-20 2006-07-05 联邦科学和工业研究组织 控制基因表达
ATE418730T1 (de) 1998-08-20 2009-01-15 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von potenziellen verbindungen für das auffinden von einem anti- tumor-arzneistoff
RU2268744C2 (ru) 1999-07-14 2006-01-27 Ново Нордиск А/С ПРИМЕНЕНИЕ FVIIa ИЛИ АНТАГОНИСТА ТКАНЕВОГО ФАКТОРА ДЛЯ РЕГУЛЯЦИИ ГЕННОЙ ЭКСПРЕССИИ И КЛЕТОЧНОЙ МИГРАЦИИ ИЛИ ХЕМОТАКСИСА
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
DK1254169T3 (da) * 1999-12-30 2007-08-06 Harvard College Fremgangsmåde vedrörende modulering af aktivitet af Th2-celledelmængde ved modulering af aktivitet af XBP-1
AU2001234721B8 (en) * 2000-01-31 2006-07-27 Munin Corporation Human Cyr61
EP1892250A3 (de) * 2000-01-31 2008-09-17 Munin Corporation CYR61-Zusammensetzungen und Verfahren
US7037332B2 (en) * 2000-03-15 2006-05-02 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
AU2001276868A1 (en) * 2000-07-11 2002-01-21 Human Genome Sciences, Inc. Connective tissue growth factor-2
PT1642885E (pt) 2000-08-29 2009-12-17 Biocon Ltd Utilização de uma composição farmacêutica contendo um derviado de ácido para-aminofenilacético para o tratamento de estados inflamatórios do tracto gastrointestinal
JP2005508133A (ja) 2001-01-11 2005-03-31 キュラジェン コーポレイション タンパク質およびそれをコードする核酸
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
CA2508880C (en) 2002-12-16 2018-02-06 Technion Research And Development Foundation Ltd. Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same
WO2004090109A2 (en) * 2003-03-31 2004-10-21 Munin Corporation Ccn3 compositions and methods
JP2004315480A (ja) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi 前立腺疾患治療用医薬組成物
WO2005040191A2 (en) * 2003-06-20 2005-05-06 Munin Corporation Ccn1 compositions and methods
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
PL1649013T3 (pl) 2003-06-27 2016-07-29 Depuy Synthes Products Inc Regeneracja i naprawa chrząstki i kości z wykorzystaniem komórek poporodowych
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US20050177885A1 (en) * 2004-02-09 2005-08-11 Lau Lester F. CCN1 transgenic animals
EP1773767B1 (de) 2004-07-07 2016-03-09 Biocon Limited Synthese von azogebundenen, das immunsystem regulierenden verbindungen
CA2589041C (en) * 2004-12-23 2019-08-20 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
JP5425399B2 (ja) 2004-12-23 2014-02-26 エシコン・インコーポレイテッド 産褥由来細胞を用いたパーキンソン病および関連の障害の治療
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
WO2007026353A2 (en) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Media for culturing stem cells
CN101374946B (zh) 2005-12-16 2017-07-18 伊西康公司 用于在组织相容性不匹配的移植中抑制有害的免疫反应的组合物和方法
US8741638B2 (en) 2005-12-19 2014-06-03 DePuy Synthes Products, LLC In vitro expansion of postpartum-derived cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9040297B2 (en) 2006-08-02 2015-05-26 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
AU2008308531B2 (en) 2007-10-05 2014-04-24 Ethicon, Incorporated Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
ES2621610T3 (es) * 2007-12-27 2017-07-04 DePuy Synthes Products, Inc. Tratamiento de la degeneración de discos intervertebrales utilizando células derivadas de tejido cordón umbilical humano
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
CN101747435B (zh) * 2008-12-18 2013-06-19 上海市免疫学研究所 一种中和cyr61的单克隆抗体(杂交瘤)及其应用
ES2665883T3 (es) 2008-12-19 2018-04-30 DePuy Synthes Products, Inc. Tratamiento de enfermedades y trastornos pulmonares y pulmonares
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
EP2411504B1 (de) 2009-03-26 2017-05-10 DePuy Synthes Products, Inc. Humane nabelschnur gewebezellen in der alzheimer therapie
TW201102086A (en) * 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP2540742A4 (de) * 2009-12-04 2014-02-12 Shanghai Inst Of Immunology Monoklonale antikörper gegen das protein cyr61 und anwendungen davon
WO2011107590A1 (en) 2010-03-04 2011-09-09 Wolfgang Poller Cnn1 (cyr61) for prevention and therapy of inflammatory disease
DE102010010288A1 (de) 2010-03-04 2011-09-08 Wolfgang Poller CCN1 zur Prävention und Therapie von entzündlichen Erkrankungen
SG191028A1 (en) 2010-12-06 2013-07-31 Thd Spa Method for the diagnosis of a carcinoma and uses thereof
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
AU2012358810B2 (en) 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
US10092607B2 (en) 2013-04-12 2018-10-09 MangoGen Pharma, Inc. Therapeutic viral microparticles for promoting stent biofunctionality and wound healing in vertebrate individuals
WO2015013875A1 (zh) * 2013-07-30 2015-02-05 杭州微基质生物科技有限公司 一种全能干细胞培养方法
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN110938128B (zh) * 2019-11-08 2021-07-13 上海交通大学 一种生物活性多肽pkcpkcdkevyfaervtsl及其制备方法和应用
CH716377B1 (it) * 2020-08-05 2020-12-30 Contrad Swiss Sa Idrogel ad applicazione topica efficace nel prevenire e/o attenuare la degenerazione della cartilagine.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JPH05255397A (ja) * 1991-01-18 1993-10-05 Bristol Myers Squibb Co ＴＧＦ−β誘導遺伝子系統群
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
PT804562E (pt) 1994-07-12 2003-02-28 Human Genome Sciences Inc Factor 2 de crescimento de tecido conjuntivo
WO1997033995A2 (en) 1996-03-15 1997-09-18 Munin Corporation Extracellular matrix signalling molecules
EP0907719A4 (de) 1996-03-20 2003-02-19 Human Genome Sciences Inc Menschliches zytokinpolypeptid

Also Published As

Publication number Publication date
ATE259419T1 (de) 2004-02-15
US6413735B1 (en) 2002-07-02
US7064185B2 (en) 2006-06-20
HK1018707A1 (en) 2000-01-04
CN1222193A (zh) 1999-07-07
EP0888452A2 (de) 1999-01-07
JP2000506732A (ja) 2000-06-06
EP0888452B1 (de) 2004-02-11
DK0888452T3 (da) 2004-06-14
DE69727558T2 (de) 2004-12-16
CA2248549A1 (en) 1997-09-18
CN1263852C (zh) 2006-07-12
WO1997033995A2 (en) 1997-09-18
US20020150986A1 (en) 2002-10-17
JP4307552B2 (ja) 2009-08-05
AU733382B2 (en) 2001-05-10
AU2329697A (en) 1997-10-01
US20060257965A1 (en) 2006-11-16
WO1997033995A3 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
DE69727558D1 (de) Humanes cyr61, ein signalmolekül der extrazellulaeren matrix
IL195337A0 (en) Cyr61 compositions and methods
EP0686161A4 (de) Alpha untereinheit des humanen beta-2 integrins
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
DE69535641D1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE69430130T2 (de) Polypeptide von der semaphorin-genfamilie
BR9708518A (pt) Moduladores de fator associado a receptor tnf (traf) sua preparação e uso
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
Perlson et al. From snails to sciatic nerve: retrograde injury signaling from axon to soma in lesioned neurons
ATE335818T1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
BR9913942A (pt) Polinucleotìdeo e polipeptìdeo isolado, vetor de expressão, célula cultivada, constructo de dna codificador de uma proteìna de fusão, processos de produção de uma proteìna, de fusão de um polipeptìdeo e de um anticorpo para o polipeptìdeo e de detecção, em uma amostra de teste, da presença de um modulador da atividade da proteìna zalpha11 e de um ligante de receptor zalpha11 dentro de uma amostra de teste, e, anticorpo
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
Yamada et al. Biological activity of laminin peptide‐conjugated alginate and chitosan matrices
DE69737766D1 (de) Zusammensetzungen von stammzellfaktor (scf)-analogen und auf diese bezogene verfahren
Hozumi et al. Mixed peptide–chitosan membranes to mimic the biological activities of a multifunctional laminin α1 chain LG4 module
DK0968288T3 (da) z219a, en human homolog til 2-19 protein
EP1892250A3 (de) CYR61-Zusammensetzungen und Verfahren
ATE408688T1 (de) Polypeptide zur modulierung des überlebens von zellen
DE69631624D1 (de) Antikörper gegen menschliches restrictin
MX9708107A (es) Subunidad alfa de integrina beta 2 humana.
Podyma Cell Cycle Under Control of Glycosaminoglycans?!
WO2001000664A3 (en) Secreted alpha-helical protein-36

Legal Events

Date Code Title Description
8364 No opposition during term of opposition